[Table/Fig-3]:
Demographic features and the results of immunohistochemical evaluation
Diabetic patients | Age &Gender | VEGF | Non Diabetic patients | Age & Gender | VEGF | ||
---|---|---|---|---|---|---|---|
HG | DG | HG | DG | ||||
1 | 42/F | II | IV | 1 | 50/M | I | II |
2 | 50/M | II | IV | 2 | 53/M | I | II |
3 | 46/M | I | IV | 3 | 52/F | 0 | II |
4 | 45/M | II | IV | 4 | 40/M | I | II |
5 | 47//F | II | III | 5 | 53/M | I | III |
6 | 42/M | II | IV | 6 | 45/M | 0 | II |
7 | 45/M | II | III | 7 | 53/M | 0 | II |
8 | 48/M | I | IV | 8 | 45/F | I | III |
9 | 45/M | II | IV | 9 | 53/M | 0 | II |
10 | 47/F | II | IV | 10 | 53/F | 0 | III |
11 | 51/M | I | III | 11 | 49/M | 0 | III |
12 | 50/M | II | IV | 12 | 43/M | I | II |
13 | 48/M | I | III | 13 | 52/M | 0 | III |
14 | 44/F | II | IV | 14 | 52/M | 0 | II |
15 | 53/M | II | III | 15 | 54/M | I | II |
16 | 49/M | I | IV | 16 | 49/M | I | III |
17 | 53/M | II | IV | 17 | 55/M | 0 | III |